Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics’ PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic therapy. Twenty patients will be enrolled and followed up for 12 months.
In this first cohort, patients experienced a pronounced and clinically relevant decrease in pain of more than 40%, reaching a maximum at six months post-treatment.
The results suggest that one dose of PREOB may progressively stimulate bone remodelling, with a bone formation-to-resorption ratio more favorable than that generally reported with other anti-osteoporotic agents in the same patient population.
Previous results released in mid-2015 from the PREOB Phase IIA trial indicated migration of intravenously-injected cells to the bones, with no treatment-related safety concerns in the 1st patient cohort.
Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics' PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic...
Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics’ PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic therapy. Twenty patients will be enrolled and followed up for 12 months.
In this first cohort, patients experienced a pronounced and clinically relevant decrease in pain of more than 40%, reaching a maximum at six months post-treatment.
The results suggest that one dose of PREOB may progressively stimulate bone remodelling, with a bone formation-to-resorption ratio more favorable than that generally reported with other anti-osteoporotic agents in the same patient population.
Previous results released in mid-2015 from the PREOB Phase IIA trial indicated migration of intravenously-injected cells to the bones, with no treatment-related safety concerns in the 1st patient cohort.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
